Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number.

Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease. Hum Genet (2013) 2.44

Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One (2009) 1.67

SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One (2010) 1.45

Genetic Interactions between the Members of the SMN-Gemins Complex in Drosophila. PLoS One (2015) 1.40

Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol (2011) 1.32

Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology (2012) 1.31

Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci Transl Med (2009) 1.30

A degron created by SMN2 exon 7 skipping is a principal contributor to spinal muscular atrophy severity. Genes Dev (2010) 1.27

The RNA binding protein hnRNP Q modulates the utilization of exon 7 in the survival motor neuron 2 (SMN2) gene. Mol Cell Biol (2008) 1.27

Survival motor neuron gene 2 silencing by DNA methylation correlates with spinal muscular atrophy disease severity and can be bypassed by histone deacetylase inhibition. Hum Mol Genet (2008) 1.26

An approximately 140-kb deletion associated with feline spinal muscular atrophy implies an essential LIX1 function for motor neuron survival. Genome Res (2006) 1.25

SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One (2011) 1.19

SMN transcript levels in leukocytes of SMA patients determined by absolute real-time PCR. Eur J Hum Genet (2010) 1.02

Severe SMA mice show organ impairment that cannot be rescued by therapy with the HDACi JNJ-26481585. Eur J Hum Genet (2012) 0.96

Spinal muscular atrophy: an update on therapeutic progress. Biochim Biophys Acta (2013) 0.93

Disease mechanisms and therapeutic approaches in spinal muscular atrophy. J Neurosci (2015) 0.92

Robust quantification of the SMN gene copy number by real-time TaqMan PCR. Neurogenetics (2007) 0.92

Advances in therapeutic development for spinal muscular atrophy. Future Med Chem (2014) 0.89

A natural history study of late onset spinal muscular atrophy types 3b and 4. J Neurol (2008) 0.89

Genetic and expression studies of SMN2 gene in Russian patients with spinal muscular atrophy type II and III. BMC Med Genet (2011) 0.88

SMA valiant trial: a prospective, double-blind, placebo-controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle Nerve (2014) 0.88

Therapeutic developments in spinal muscular atrophy. Ther Adv Neurol Disord (2010) 0.87

Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. BMC Neurol (2011) 0.87

Transcriptome profiling of spinal muscular atrophy motor neurons derived from mouse embryonic stem cells. PLoS One (2014) 0.86

Dual masking of specific negative splicing regulatory elements resulted in maximal exon 7 inclusion of SMN2 gene. Mol Ther (2013) 0.86

The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype. Am J Hum Genet (2016) 0.85

Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res (2016) 0.84

Mechanistic principles of antisense targets for the treatment of spinal muscular atrophy. Future Med Chem (2015) 0.84

Clinical and molecular cross-sectional study of a cohort of adult type III spinal muscular atrophy patients: clues from a biomarker study. Eur J Hum Genet (2012) 0.83

SMN1 and SMN2 copy numbers in cell lines derived from patients with spinal muscular atrophy as measured by array digital PCR. Mol Genet Genomic Med (2015) 0.83

Chemical genetic approaches to probing cell death. Curr Opin Chem Biol (2006) 0.83

Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. Front Mol Biosci (2016) 0.83

Spinal muscular atrophy genetic counseling access and genetic knowledge: parents' perspectives. J Child Neurol (2007) 0.82

Diverse role of Survival Motor Neuron Protein. Biochim Biophys Acta (2017) 0.81

Analysis of the fibroblast growth factor system reveals alterations in a mouse model of spinal muscular atrophy. PLoS One (2012) 0.81

Cross-disease comparison of amyotrophic lateral sclerosis and spinal muscular atrophy reveals conservation of selective vulnerability but differential neuromuscular junction pathology. J Comp Neurol (2015) 0.81

Survival analysis of spinal muscular atrophy type I. Korean J Pediatr (2010) 0.81

Bone health and associated metabolic complications in neuromuscular diseases. Phys Med Rehabil Clin N Am (2012) 0.80

Molecular Mechanisms of Neurodegeneration in Spinal Muscular Atrophy. J Exp Neurosci (2016) 0.80

Biomarkers in rare disorders: the experience with spinal muscular atrophy. Int J Mol Sci (2010) 0.79

Molecular Analysis of Spinal Muscular Atrophy: A genotyping protocol based on TaqMan(®) real-time PCR. Genet Mol Biol (2012) 0.79

Applicability of histone deacetylase inhibition for the treatment of spinal muscular atrophy. Neurotherapeutics (2013) 0.78

Of SMN in mice and men: a therapeutic opportunity. J Clin Invest (2011) 0.78

Protective effects of butyrate-based compounds on a mouse model for spinal muscular atrophy. Exp Neurol (2016) 0.78

Pharmacokinetics, pharmacodynamics, and efficacy of a small-molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy. Hum Mol Genet (2016) 0.78

Decay in survival motor neuron and plastin 3 levels during differentiation of iPSC-derived human motor neurons. Sci Rep (2015) 0.77

Polar body biopsy in the diagnosis of monogenic diseases: the birth of three healthy children. Dtsch Arztebl Int (2009) 0.77

Genetic Modifiers for Neuromuscular Diseases. J Neuromuscul Dis (2015) 0.77

Clinical and Genetic Study of Algerian Patients with Spinal Muscular Atrophy. J Neurodegener Dis (2013) 0.75

Joint effect of the SMN2 and SERF1A genes on childhood-onset types of spinal muscular atrophy in Serbian patients. J Hum Genet (2015) 0.75

Systems biology investigation of cAMP modulation to increase SMN levels for the treatment of spinal muscular atrophy. PLoS One (2014) 0.75

Multiple effects of curcumin on promoting expression of the exon 7-containing SMN2 transcript. Genes Nutr (2015) 0.75

Modeling the differential phenotypes of spinal muscular atrophy with high-yield generation of motor neurons from human induced pluripotent stem cells. Oncotarget (2017) 0.75

Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet J Rare Dis (2017) 0.75

Identification and characterization of a spinal muscular atrophy-determining gene. Cell (1995) 17.41

The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet (2000) 5.38

SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum Mol Genet (2005) 5.23

Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet (2001) 4.50

International SMA consortium meeting. (26-28 June 1992, Bonn, Germany). Neuromuscul Disord (1992) 3.26

Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet (1978) 2.95

An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat (2000) 2.71

Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol (1995) 2.56

Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet (2003) 2.51

Genetic homogeneity between childhood-onset and adult-onset autosomal recessive spinal muscular atrophy. Lancet (1995) 2.40

When is a deletion not a deletion? When it is converted. Am J Hum Genet (1997) 2.38

Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals. Hum Mol Genet (1995) 2.34

Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy. Am J Hum Genet (1995) 2.33

Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol (2003) 2.28

Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med (2002) 2.26

Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype-phenotype correlation, and implications for genetic counseling. Am J Hum Genet (1999) 2.21

Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. Biochem Biophys Res Commun (1995) 2.06

De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling. Am J Hum Genet (1997) 2.05

Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet (2004) 1.89

Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med Genet A (2004) 1.79

Characterization of survival motor neuron (SMNT) gene deletions in asymptomatic carriers of spinal muscular atrophy. Hum Mol Genet (1996) 1.61

Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1. Hum Genet (2003) 1.52

Inverse correlation between SMN1 and SMN2 copy numbers: evidence for gene conversion from SMN2 to SMN1. Eur J Hum Genet (2003) 1.48

Allelic association and deletions in autosomal recessive proximal spinal muscular atrophy: association of marker genotype with disease severity and candidate cDNAs. Hum Mol Genet (1995) 1.45

Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet (2005) 1.38

Hybrid survival motor neuron genes in patients with autosomal recessive spinal muscular atrophy: new insights into molecular mechanisms responsible for the disease. Am J Hum Genet (1996) 1.32

Deletion and conversion in spinal muscular atrophy patients: is there a relationship to severity? Ann Neurol (1997) 1.23

Survival motor neuron protein modulates neuron-specific apoptosis. Proc Natl Acad Sci U S A (2000) 1.14

Apparent gene conversions involving the SMN gene in the region of the spinal muscular atrophy locus on chromosome 5. Am J Hum Genet (1996) 1.10

Prevalence of SMN1 deletion and duplication in carrier and normal populations: implication for genetic counselling. J Med Genet (2003) 0.97

Detection of the survival motor neuron (SMN) genes by FISH: further evidence for a role for SMN2 in the modulation of disease severity in SMA patients. Hum Mol Genet (1999) 0.95

Involvement of survival motor neuron (SMN) protein in cell death. Hum Mol Genet (2002) 0.93

SMN gene deletions in adult-onset spinal muscular atrophy. Lancet (1996) 0.86

Genetic basis of adult-onset spinal muscular atrophy. Lancet (1995) 0.82

Spinal muscular atrophy: state-of-the-art and therapeutic perspectives. Amyotroph Lateral Scler Other Motor Neuron Disord (2002) 0.79

Presymptomatic diagnosis of SMA III by genotype analysis. Am J Med Genet (1993) 0.75

Parallel human genome analysis: microarray-based expression monitoring of 1000 genes. Proc Natl Acad Sci U S A (1996) 24.18

[Hemoglobins, XXXIII. Note on the Sequence of the hemoglobins of the horse (author's transl)]. Hoppe Seylers Z Physiol Chem (1980) 9.05

The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet (2000) 5.38

A genetic mapping system in Caenorhabditis elegans based on polymorphic sequence-tagged sites. Genetics (1992) 5.37

The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science (2001) 4.89

Johann Christian Reil's training scheme for medical auxiliaries. Med Hist (1975) 2.77

Interaction between a putative mechanosensory membrane channel and a collagen. Science (1996) 2.52

Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul Disord (2011) 2.47

The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther (1995) 2.39

The orderly progression of melanoma nodal metastases. Ann Surg (1994) 2.16

Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. Br J Cancer (1998) 2.11

Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res (1999) 2.09

Officiers de santé: the second-class doctors of nineteenth-century France. Med Hist (1978) 1.96

Structure and organization of the highly repeated and interspersed 1.3 kb EcoRI-Bg1II sequence family in mice. Nucleic Acids Res (1980) 1.89

Randomized 4-week exercise program in patients with impaired left ventricular function. Circulation (1991) 1.77

Characterization of the gene encoding human sarcolipin (SLN), a proteolipid associated with SERCA1: absence of structural mutations in five patients with Brody disease. Genomics (1997) 1.70

An agrin minigene rescues dystrophic symptoms in a mouse model for congenital muscular dystrophy. Nature (2001) 1.65

Cyclosporine A treatment for Ullrich congenital muscular dystrophy: a cellular study of mitochondrial dysfunction and its rescue. Brain (2008) 1.65

The role of polymeric surface smoothness of biliary stents in bacterial adherence, biofilm deposition, and stent occlusion. Gastrointest Endosc (1993) 1.64

Bacteremia and endocarditis caused by a Gordonia species in a patient with a central venous catheter. Emerg Infect Dis (2000) 1.61

[Tetrafluorosuccinic anhydride, a new reagent for the specific and reversible masking of amino groups in proteins]. Hoppe Seylers Z Physiol Chem (1968) 1.61

Congenital heart disease is a feature of severe infantile spinal muscular atrophy. J Med Genet (2008) 1.57

Coyotes (Canis latrans) as the reservoir for a human pathogenic Bartonella sp.: molecular epidemiology of Bartonella vinsonii subsp. berkhoffii infection in coyotes from central coastal California. J Clin Microbiol (2000) 1.56

Increased perfusion and angiogenesis in a hindlimb ischemia model with plasmid FGF-2 delivered by noninvasive electroporation. Gene Ther (2010) 1.56

Effect of contraception provided at termination of pregnancy and incidence of subsequent termination of pregnancy. BJOG (2012) 1.53

Reduced survival motor neuron (Smn) gene dose in mice leads to motor neuron degeneration: an animal model for spinal muscular atrophy type III. Hum Mol Genet (2000) 1.50

Epidemiology of Bartonella infection in domestic cats in France. Vet Microbiol (2001) 1.49

Coinfection with Bartonella clarridgeiae and Bartonella henselae and with different Bartonella henselae strains in domestic cats. J Clin Microbiol (1997) 1.46

The recurrence risk for neural tube defects in the United States: a collaborative study. Am J Med Genet (1980) 1.45

Inflammatory demyelinating neuropathy in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis (CAPD) Perit Dial Int (1998) 1.43

Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome. Clin Genet (2007) 1.41

Outcome with calcium channel antagonists after myocardial infarction: a community-based study. J Am Coll Cardiol (1998) 1.39

High frequency of co-segregating CLCN1 mutations among myotonic dystrophy type 2 patients from Finland and Germany. J Neurol (2008) 1.37

Coenzyme Q10 deficiency and isolated myopathy. Neurology (2006) 1.32

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol (2000) 1.30

Theory and in vivo application of electroporative gene delivery. Mol Ther (2000) 1.30

Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst (1987) 1.28

Bartonella birtlesii sp. nov., isolated from small mammals (Apodemus spp.). Int J Syst Evol Microbiol (2000) 1.27

High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna) (2004) 1.26

Scapuloperoneal syndrome type Kaeser and a wide phenotypic spectrum of adult-onset, dominant myopathies are associated with the desmin mutation R350P. Brain (2007) 1.26

Rapsyn N88K is a frequent cause of congenital myasthenic syndromes in European patients. Neurology (2003) 1.24

Cytochrome c oxidase deficiency due to mutations in SCO2, encoding a mitochondrial copper-binding protein, is rescued by copper in human myoblasts. Hum Mol Genet (2001) 1.24

[Complete and automatic degradation of peptides acording to the quadrol method]. Hoppe Seylers Z Physiol Chem (1970) 1.24

FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patients. J Med Genet (2004) 1.24

Comparison of processes and intermediate outcomes between South Asian and European patients with diabetes in Blackburn, north-west England. Diabet Med (2005) 1.22

Leigh syndrome caused by mutations in the flavoprotein (Fp) subunit of succinate dehydrogenase (SDHA). J Neurol Neurosurg Psychiatry (2006) 1.21

EFNS guideline on diagnosis and management of limb girdle muscular dystrophies. Eur J Neurol (2007) 1.20

Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-kappa B activation, and c-Jun kinase activation. J Immunol (1998) 1.20

Toxicity of anticancer agents mediated by electroporation in vitro. Anticancer Drugs (2000) 1.19

Comparative phylogeography of African savannah ungulates. Mol Ecol (2012) 1.18

The impact of the social network, stigma and empowerment on the quality of life in patients with schizophrenia. Eur Psychiatry (2010) 1.17

Optimization of cutaneous electrically mediated plasmid DNA delivery using novel electrode. Gene Ther (2006) 1.17

The complete amino acid sequence of the basic nuclear protein of bull spermatozoa. Biochim Biophys Acta (1972) 1.17

Detection of submicroscopic lymph node metastases with polymerase chain reaction in patients with malignant melanoma. Ann Surg (1994) 1.16

Novel electrode designs for electrochemotherapy. Biochim Biophys Acta (1997) 1.15

Dystrophin expression in muscles of mdx mice after adenovirus-mediated in vivo gene transfer. Hum Gene Ther (1996) 1.14

Kinetics of Bartonella birtlesii infection in experimentally infected mice and pathogenic effect on reproductive functions. Infect Immun (2001) 1.13

Refinement of the clinical phenotype in musk-related congenital myasthenic syndromes. Neurology (2009) 1.11

A refined diagnostic algorithm for Bethlem myopathy. Neurology (2008) 1.10

Analysis of the prion protein gene in thalamic dementia. Neurology (1992) 1.09

[The sequence of beta-lactoglobulin (author's transl)]. Hoppe Seylers Z Physiol Chem (1973) 1.09

Histologic evaluation of full and partial thickness lateral repositioned flaps: a pilot study. J Periodontol (1971) 1.08

Direct molecular typing of Borrelia burgdorferi sensu lato species in synovial samples from patients with lyme arthritis. J Clin Microbiol (2000) 1.07

[On the phylogenesis of hemoglobin: research on rabbit hemoglobin (Caniculus)]. Hoppe Seylers Z Physiol Chem (1966) 1.06

Adenovirus-mediated gene transfer of the tumor suppressor, p53, induces apoptosis in postmitotic neurons. J Cell Biol (1996) 1.05

[The complete automatic sequence analysis of peptides with the aid of quadrol]. Hoppe Seylers Z Physiol Chem (1971) 1.05

Tea tree oil as an alternative topical decolonization agent for methicillin-resistant Staphylococcus aureus. J Hosp Infect (2000) 1.05

Characterization of human muscle type cofilin (CFL2) in normal and regenerating muscle. Eur J Biochem (2001) 1.05

Decreased aminoacylation of mutant tRNAs in MELAS but not in MERRF patients. Hum Mol Genet (2000) 1.05

U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping. Cell Mol Life Sci (2003) 1.04

Flow cytometric determination of E-selectin, vascular cell adhesion molecule-1, and intercellular cell adhesion molecule-1 in formaldehyde-fixed endothelial cell monolayers. Cytometry (2000) 1.04

Screening for carnitine palmitoyltransferase II deficiency by tandem mass spectrometry. J Inherit Metab Dis (2002) 1.03

Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants. Gene Ther (1994) 1.03

Primary hyperparathyroidism in patients with breast carcinoma. Arch Surg (1970) 1.02

Electrically mediated plasmid DNA delivery to hepatocellular carcinomas in vivo. Gene Ther (2000) 1.02

Regression of subcutaneous B16 melanoma tumors after intratumoral delivery of an IL-15-expressing plasmid followed by in vivo electroporation. Cancer Gene Ther (2006) 1.02

Phosphoenolpyruvate carboxytransphosphorylase. II. Crystallization and properties. J Biol Chem (1966) 1.02

In vivo electroporation of plasmids encoding GM-CSF or interleukin-2 into existing B16 melanomas combined with electrochemotherapy induces long-term antitumour immunity. Melanoma Res (2000) 1.02

Differential short-term transduction efficiency of adult versus newborn mouse tissues by adenoviral recombinants. Exp Mol Pathol (1995) 1.01

Late onset in dysferlinopathy widens the clinical spectrum. Neuromuscul Disord (2008) 1.01

Intralesional bleomycin-mediated electrochemotherapy in 20 patients with basal cell carcinoma. J Am Acad Dermatol (1997) 1.01

Bleomycin-mediated electrochemotherapy of basal cell carcinoma. J Am Acad Dermatol (1996) 1.01

Hypochlorite-modified low density lipoprotein inhibits nitric oxide synthesis in endothelial cells via an intracellular dislocalization of endothelial nitric-oxide synthase. J Biol Chem (2001) 1.00

[Hyperbaric oxygen therapy in retinal artery occlusion]. Ophthalmologe (2000) 1.00

Missense mutations of ACTA1 cause dominant congenital myopathy with cores. J Med Genet (2004) 1.00

Immunomodulation by electrically enhanced delivery of plasmid DNA encoding IL-12 to murine skeletal muscle. Mol Ther (2001) 1.00

Elevated hepatic chemerin mRNA expression in human non-alcoholic fatty liver disease. Eur J Endocrinol (2013) 0.99

Laparoscopic Fowler-Stephens orchiopexy for the high abdominal testis. J Urol (1999) 0.99

Electroporation-mediated delivery of a naked DNA plasmid expressing VEGF to the porcine heart enhances protein expression. Gene Ther (2009) 0.99

Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol (1996) 0.99

MR imaging of the breast in patients with invasive lobular carcinoma. AJR Am J Roentgenol (2001) 0.99

Mapping of the spinal muscular atrophy (SMA) gene to a 750-kb interval flanked by two new microsatellites. Eur J Hum Genet (1995) 0.98

Corynebacterium durum sp. nov., from human clinical specimens. Int J Syst Bacteriol (1997) 0.98

[Respiration at high altitudes, phosphate-protein interaction: the sequence of hemoglobins from guinea pig and dromedary (author's transl)]. Hoppe Seylers Z Physiol Chem (1979) 0.98

Detection and quantitation of cell-cell electrofusion products by flow cytometry. Anal Biochem (1994) 0.98

Ty4, a novel low-copy number element in Saccharomyces cerevisiae: one copy is located in a cluster of Ty elements and tRNA genes. Nucleic Acids Res (1989) 0.98

Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited. Neuropathol Appl Neurobiol (2007) 0.98

Electroporation-mediated gene transfer directly to the swine heart. Gene Ther (2012) 0.97

Regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase in minimal deviation hepatoma 7288C. Immunological measurements in hepatoma tissue culture cells. J Biol Chem (1977) 0.97

A common mutation (epsilon1267delG) in congenital myasthenic patients of Gypsy ethnic origin. Neurology (1999) 0.97